. Author manuscript; available in PMC: 2023 Jul 24.

Published in final edited form as: J Clin Rheumatol. 2021 Apr 1;27(3):87–91. doi: 10.1097/RHU.0000000000001170

TABLE 2.

JIA Disease Characteristics

	Active Untreated and Quiescent Treated JIA (n = 59)	Active Untreated JIA (n = 27)	Quiescent Treated JIA (n = 32)
JIA category Polyarticular	14 (23.7%)	6 (22.2%)	8 (25.0%)
Psoriatic	12 (20.3%)	6 (22.2%)	6 (18.8%)
Spondyloarthropathy	33 (56.0%)	15 (55.6%)	18 (56.2%)
Disease duration (mean)	6–12 mo	3–6 mo	2–3 y
JADAS-71 scores, median (interquartile range)	5.5 (2.5, 12)	12 (6.4, 18.5)	3 (0.5, 5)
Medications NSAIDs	40 (67.8%)	27 (100.0%)	13 (40.6%)
Methotrexate	11 (18.6%)	0 (0.0%)	11 (34.4%)
Anti–tumor necrosis factor	21 (35.6%)	0 (0.0%)	21 (65.6%)
ANA⁺	28 (47.4%)	10 (37.0%)	17 (53.1%)
B27⁺	11 (18.6%)	4 (14.8%)	16 (50.0%)
RF⁺	4 (6.8%)	2 (7.4%)	13 (40.6%)
CCP⁺	8 (13.5%)	4 (14.8%)	11 (34.4%)